Welcome to visit Acta Anatomica Sinica! Today is
Chinese
Effects of recombinant human endostatin on the expression of vascular endothelial growth factor, transforming growth factor-β1 and basic fibroblast growth factor on hypertrophic scar in rabbit ears
ZHANG Xiao-ming YU Jian HUANG Xue-ying* DENG Xue-fei LI Xiao-jing
Acta Anatomica Sinica ›› 2015, Vol. 46 ›› Issue (1) : 101-105.
Effects of recombinant human endostatin on the expression of vascular endothelial growth factor, transforming growth factor-β1 and basic fibroblast growth factor on hypertrophic scar in rabbit ears
Objective To investigate the effect of rhEndostatin on hypertrophic scar in rabbit ears and its mechanism. Methods Twenty healthy New Zealand big-eared white rabbits were divided equally into normal control group, model group, normal saline (NS) control group, rhEndostatin treatment group and triamcinolone acetonide (TA) control group. All groups were reproducing animal model of hyperplastic scar except normal control group, 1 cm ×1 cm size of the wound were made on ventral side of rabbit ears. Treatments were administered starting on postoperative days 28. rhEndostatin (100μl) was injected intradermally into the wounds of rhEndostatin treatment group with scar block local injection, NS control group injected with saline, the injection frequency of the two groups was once every other day for 6 successive times. The wounds treated with TA received the same doses, and the injection frequency was once a week, a total of 2 times. For model group, wounds received no injections. At postoperative days 47, collected scars and normal skin specimens, observe the change of rabbit ear scar in all groups, and the immunohistochemical method was also used to detect the distribution of vascular endothelial growth factor-β1（VEGF）, transforming growth factor-β1（TGF-β1）and basic fibroblast growth factor（bFGF）positive signals. Results The scar morphological change appeared to be smaller, softer, flatter, and lighter in color in the rhEndostatin treatment group than those in the model group and NS control group. The intensities of immunohistochemical positive staining for VEGF and TGF-β1 were lower in rhEndostatin treatment group than those in the model group. The bFGF immunohistochemical positive staining intensity was increased significantly(P<0.01). Conclusion rhEndostatin can inhibit the hypertrophic scar in rabbit ears, the mechanism might be related to expression of VEGF, TGF-β1 and bFGF.
Hypertrophic scar /
Recombinant human endostatin /
Vascular endothelial growth factor /
Transforming growth factor β1 /
/
Basic fibroblast growth factor /
/
Immunohistochemical SP method /
/
Rabbit
［1］Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids:pathomechanisms and current and emerging treatment strategies［J］. Mol Med, 2011, 17(1-2) : 113-125.
［2］O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth［J］. Cell, 1997, 88(2) : 277-285.
［3］Xia LJ, Chen FH, Huang XY, et al. Effect of recombinant human endostatin on expression of vascular endothelial cell growth factor in adjuvant arthritis synovium tissue ［J］. Chin J Clin Pharmacol Ther, 2006, 11(7) : 760-763. (in Chinese)
夏丽娟, 陈飞虎, 黄学应, 等. 重组人内抑素对佐剂性关节炎大鼠滑膜组织血管内皮生长因子表达的影响［J］. 中国临床药理学与治疗学, 2006, 11 (7) : 760-763.
［4］Yu J, Zhang XM, Huang XY, et al. Study of the inhibitory effects of recombinant human endostatin on hypertrophic scars［J］. Acta Universitatis Medicinalis Anhui, 2014, 49(7):891-895.(in Chinese)
余建, 张晓明, 黄学应, 等. 重组人内抑素抑制创面瘢痕增生的实验研究［J］.安徽医科大学学报, 2014, 49(7) : 891-895.
［5］Morris DE, Wu L, Zhao LL, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies［J］. Plast Reconstr Surg, 1997, 100(3) : 674-681.
［6］Sidgwick GP, Bayat A. Extracellular matrix molecules implicated in hypertrophic and keloid scarring［J］. J Eur Acad Dermatol Venereol, 2012, 26(2) : 141-152.
［7］Gerd G Gauglitz. Management of keloids and hypertrophic scars: current and emerging options［J］. Clin Cosmet Investig Dermatol, 2013, (6) : 103-114.
［8］Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response［J］. FASEB J, 2004, 18(7) : 816-827.
［9］Fan J, Bai SL, Yan YW, et al. Expression of Vascular endothelial growth factor and thrombospondin-1 in rat thoracic aortic aneurysm［J］. Acta Anatomica Sinica, 2012, 43(6) : 818-821. (in Chinese)
范军, 柏树令, 阎亚伟, 等. 血管内皮生长因子和血小板反应蛋白-1在大鼠胸主动脉瘤中的表达［J］. 解剖学报, 2012, 43(6) : 818-821.
［10］Shi HX, Cai L, Lin BB, et al. The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo［J］. PLoS One, 2013, 8(4) : e59966.
［11］Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing［J］. Wound Repair Regen, 2008, 16(5) : 585-601.
［12］Li WW, Talcott KE, Zhai AW, et al. The role of therapeutic angiogenesis in tissue repair and regeneration［J］. Adv Skin Wound Care, 2005, 18(9) : 491-500.
［13］Tille JC, Wood J, Mandriota SJ, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro［J］. J Pharmacol Exp Ther, 2001, 299(3) : 1073-1085.
［14］Spanholtz T, Maichle A, Niedworok C, et al. Timing and targeting of cell-based VEGF165 gene expression in ischemic tissue［J］. J Surg Res, 2009, 151(1) : 153-162.
［15］Ono I, Akasaka Y, Kikuchi R, et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds［J］. Wound Repair Regen, 2007, 15(5) : 617-623.
/
| 〈 |
|
〉 |
